Non-Hodgkin's lymphoma in children until recently had usually been rapidly progressive and fatal. The cure rate of childhood non-Hodgkin's lymphoma was disappointingly low in the 1960s, about 10-15%. Treatment regimens generally included radiotherapy to involved areas, with or without -single agent chemotherapy. A decade later remarkable progress was reported from the Memorial SloanKettering Cancer Center (Wollner et al., 1976 (Wollner et al., ,1979 . The LSA2-L2 regimen was conceived in 1971, and numerous reports of its successful application have subsequently appeared in the literature. Wollner and colleagues reported an overall 73% survival rate. Recently several programs have reported combining aggressive chemotherapy, prophylactic irradiation and intrathecal therapy in the treatment of this disease. Complete remission rates by using these combination chemotherapies have risen to 85-90% and two year survival rates have risen to 70-76% (Glatstein et al., 1974; Link et al., 1985; Sullivan et al., 1985) . This paper reports the efficacy of combined chemotherapy 'modified and less aggressive LSA2-L2 regimen' and the degree to which the results were influenced by the extent and histopathological subtypes of the disease.
Patients and methods
Between January 1983 and December 1986, 76 children with non-Hodgkin's lymphoma (except those diagnosed as having Burkitt's lymphoma by the institutional pathologist) were treated at Hacettepe Children's Hospital Oncology Unit. All patients were less than 18 years of age. There were 49 males and 27 females. Male/female ratio was 1.8 and median age was 6 years.
The extent of disease was determined (by history, physical examination, blood count, bone marrow aspiration, spinalfluid cell count and smear for white-cell morphology) two dimensional chest X-rays, bone scan of skeletal survey, intravenous pyelogram, and in some patients abdominal ultrasonography and computerized axial tomography. Routine lymphangiogram and staging laparotomy were not performed, although abdominal patients underwent a laparotomy for diagnostic, therapeutic or palliative reasons. More than half of the patients had abdominal disease (53%) either nodal or gastrointestinal primary lesions (Table  III) . Thirty-two percent of the patients had mediastinal or widespread disease and 19% had involvement of the bone marrow or central nervous system at diagnosis, in addition to disseminated disease at other sites (stage IV) (Table IV) (Table I) . Regimen II had three phases; induction, consolidation and cycles of maintenance (Table II) . Central nervous system prophylaxis in regimen II consisted of repeated injections of intrathecal methotrexate, cytosine arabinoside and hydrocortisone. Prophylactic CNS irradiation was only given to the intrathoracic lymphoma patients. Both regimens were followed for 24 months from the first day of induction.
Statistical analysis Analysis of the response to treatment focused on the time from entry into the study to the first adverse event, if any. Events defined as adverse were: no response by the completion of induction therapy, a relapse of any kind, and death. Any adverse event was considered a treatment failure. The period from entry into the study to the first adverse event is referred to below as failure-free survival. The product-limit method was used to estimate the distribution of failure-free survival and of overall survival (Peto et al., 1977) .
Results
Complete remission rate was 86.8% at the end of induction therapy. Survival rate was 80.1% in patients who had complete remission at the end of induction therapy and two year continuous complete remission rate was 64.3% in those patients. Failure-free survival for all patients was estimated to be 59.2% at 24 months and overall survival was 72.3% at 24 months (Figure 1) . Length of follow up was 17-52 months. At the time of writing, the median follow-up for patients who have had no adverse event is 28 months.
The extent of the disease at diagnosis was an important indicator of treatment response in our study. Among the patients with stage I and II the failure-free survival rate was 81.2% while it was 53.3% in stage III and IV patients at 24 months (Figure 2 ). Failure-free survival was 50% in patients with poorly differentiated lymphoma, 67.8% in patients with undifferentiated non-Burkitt's group and 75% in the unclassified group (Figure 3) .
Failure-free survival rate was 53.8% in patients with mediastinal disease and 68.3% in those with abdominal disease at 24 months (not statistically significantly different) but was only 20% in widespread non-Hodgkin's lymphoma at diagnosis (Figure 4) . Thus, failure-free survival is clearly related to the primary site of the disease in this series. Eleven patients died during treatment as a result of treatment-related sepsis, four early in the induction phase, one with systemic varicella in remission, one with iatrogenic purulent meningitis in remission and the remaining 5 patients during relapse with systemic bacterial and viral infections. Haematologic toxicities were neutropenia (28.9%) and thrombocytopenia (4%). After these deaths, we gave prophylactic antibiotic therapy (either trimethoprimsulfamethoxozole or metragyl) during induction to all stage III and IV patients.
Discussion
Non-Hodgkin's lymphomas in childhood differ considerably from those in adults in that nodular patterns are rare in children. Non-Hodgkin's lymphomas grow rapidly and disseminate early in children and the majority of patients have widespread disease at diagnosis. In the past, despite therapy, most children had a relapse within a year of diagnosis and long term survival was only about 15%.
The prognosis for childhood non-Hodgkin's lymphoma has improved dramatically in the last two decades. Because of similarities between non-Hodgkin's lymphoma and acute lymphoblastic leukaemia, a number of investigators adopted a more aggressive approach using anti-leukaemic chemotherapy in addition to radiotherapy in an attempt to reduce the incidence of distant metastasis and to prolong remission duration. This approach resulted in prolonged remission in children with localized non-Hodgkin's lymphoma and reduced the incidence of leukaemic transformation (Glatstein et al., 1974; Meadows et al., 1980 , Buyiikpamukqu et al., 1983 .
The addition of new chemotherapeutic agents and the application of novel combinations of drugs have led to gratifying improvements in survival for children with advanced non-Hodgkin's lymphoma too. Wollner et al. (1976; 1979) treated 39 children with a multidrug leukaemia programme intensified with cyclophosphamide and radiation treatment (LSA2-L2). They reported a long term disease-free survival rate of 73%. Using a leukaemia regimen intensified with cyclophosphamide and doxorubicin for non-localized advanced disease Murphy and Hustu (1980) obtained a disease free survival rate of 90% in patients with localized disease and 39% in those with disseminated disease, with 2-year relapse-free survival of 55%. In the CCSG pilot study with COMP Meadows et al. (1980) obtained a two year survival rate of 68%, without prohibitive toxicity. Anderson et al. (1983) compared modified LSA2-L2 and COMP regimens and found results for localized patients did not differ according to the regimen used, but patients treated with COMP had less toxicity. Significant treatment differences were observed in patients with non-localized disease but only within the lymphoblastic subgroups. Modified LSA2-L2 was more effective in lymphoblastic lymphoma, whereas COMP was more effective in the nonlymphoblastic groups (undifferentiated Burkitt, non-Burkitt, and histiocytic). Mott et al. (1984a) obtained 66% failure-free survival with combination chemotherapy and low dose radiotherapy in Tcell lymphoma. They also reported 75% failure-free survival for localized disease (stage I and II), and 51% for generalized disease (stage III and IV) at four years (Mott et al., 1984b) . In the latter group (with no mediastinal primary), there was no benefit to patients randomized at the end of induction chemotherapy to receive adjuvant low dose radiation to sites of previous bulky disease when compared to those not receiving such radiation.
In our study, the extent of the disease at diagnosis was an important determinant of the overall response to therapy. Among the patients with localized disease, the 2 year failurefree survival was 82.1%, while it was 53.3% in those with disseminated disease.
There was also a relationship between the primary site of the tumour and the failure-free survival rate. Among the patients with mediastinal disease, 2 year survival rate was 53.8% and while in abdominal disease, it was 73.2%.
Our diffuse poorly differentiated lymphoblastic lymphoma group's failure-free survival rate (50% in 2-year) was lower than that of the undifferentiated non-Burkitt group (66.8%) but the difference was not statistically significant.
The overall results of this trial represent a significant improvement over our own institution's historical controls. We reported 31% 2-year survival in patients treated from [1972] [1973] [1974] [1975] [1976] [1977] [1978] (Bfiyfikpamukqu et al., 1983) while our estimate of the proportion of all patients entered in the present study surviving at two years is 72.4%.
Despite this appreciable progress, it is nevertheless clear that treatment for certain subgroups (the poorly differentiated lymphocytic lymphoma and primary mediastinal form) remains unsatisfactory. For these we need more intensive or better treatment.
